Lipitor Significantly Lowered Hospitalization Costs for Patients with Heart Disease, Two New Analyses Show

NEW ORLEANS-- Pfizer announced today that Lipitor® (atorvastatin calcium) Tablets (80 mg) lowered hospitalization costs by significantly reducing the risk of cardiovascular events in patients with heart disease, according to two separate economic analyses. The data were presented at the annual meeting of the American College of Cardiology.

“One of these analyses suggests that even with the availability of low cost generics, intensive Lipitor therapy is a good economic value,” said Dr. Peter Lindgren, managing director of European Health Economics in Stockholm, Sweden, and lead investigator of the economic evaluation of the Incremental Decrease in Endpoints through Aggressive Lipid Lowering (IDEAL) trial. “The economic impact of heart attacks and strokes in the U.S. alone totals more than $400 billion in medical care and lost productivity annually.”

New IDEAL Health Economic Analysis

In a new post-hoc analysis of a subset of patients (n=999) in the IDEAL study that had acute coronary syndrome (i.e. had a heart attack less than two months prior to entering the study):

* Hospitalization costs during the five-year trial were 21 percent lower for Lipitor 80 mg ($6,427 per patient) than for simvastatin 20 mg—40 mg ($8,179 per patient).
* This finding was due to the significant 21 percent reduction in the risk of any cardiovascular event for these patients.

Even in a low cost generic market, treatment of acute coronary syndrome patients with Lipitor 80 mg is predicted to reduce cardiovascular events at an acceptable incremental cost over simvastatin 20 mg-40 mg.

On average in the U.S., coronary heart disease, including heart attacks, costs $ 96,467 in direct costs per patient, a stroke costs $59,429 and certain types of heart surgery cost $122,122.

“As physicians, payers and employers come under increasing pressure to reduce medical healthcare costs, this analysis provides them with additional support for offering intensive Lipitor therapy to help achieve improved and cost-effective cardiovascular outcomes for their patients,” said Dr. Michael Berelowitz, senior vice president of Pfizer’s global medical division.

This new analysis of patients with acute coronary syndrome is consistent with the health economic findings of the overall IDEAL trial of 8,888 patients.

Additionally, in a separate analysis of a large U.S. managed care database that was recently presented, Lipitor patients achieved a significant additional 14 percent reduction in the risk of cardiovascular events compared with patients taking simvastatin, even after adjustments for expected differences of LDL lowering based on dose.

“Together these analyses provide additional evidence for physicians who may be considering prescribing statins interchangeably using dose adjustments,” said Dr Berelowitz.

About the Overall IDEAL Trial

IDEAL was an open-label trial of 8,888 patients who had had a previous heart attack comparing Lipitor 80 mg with simvastatin 20 mg–40 mg. There was an 11 percent reduction in the primary endpoint, major coronary events, in Lipitor patients compared to simvastatin patients, but this difference did not reach statistical significance. Based on a secondary endpoint, Lipitor reduced the risk of non-fatal heart attack by a significant 17 percent and the risk of any cardiovascular events by 16 percent compared with patients taking simvastatin 20 mg—40 mg.

In a subset of these patients (n=999) who had had a heart attack less than two months prior to entering the study, Lipitor 80 mg reduced the risk of heart attacks by 46 percent, major coronary events by 34 percent, and any cardiovascular event by 21 percent compared with simvastatin 20 mg—40 mg.

New Analysis of the Treating to New Targets (TNT) Trial

In a pre-specified analysis of more than 5,300 U.S. patients with stable coronary heart disease from the TNT trial:

* Lipitor 80 mg provided significantly better clinical outcomes at almost no additional cost over five years compared with Lipitor 10 mg (the five-year cost of the 80 mg dose was $181 more).
* This finding resulted from a significant 15 percent reduction in both cardiovascular hospitalizations and a significant 27 percent reduction in revascularizations.

About the overall TNT Trial

The five-year TNT study involved 10,000 patients with both heart disease and elevated LDL levels. In this study, patients taking Lipitor 80 mg had a significant 22 percent reduction in the risk of major cardiovascular events over and above patients taking Lipitor 10 mg. In addition, patients treated with Lipitor 80 mg had a significant 26 percent reduction in the risk of hospitalization for heart failure.